combretastatin has been researched along with serine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, YC; Xian, LJ; Zou, Y | 1 |
| Lenihan, DJ; Subbiah, IM; Tsimberidou, AM | 1 |
| Azzariti, A; Gnoni, A; Numico, G; Paradiso, A; Porcelli, L; Quatrale, AE | 1 |
2 review(s) available for combretastatin and serine
| Article | Year |
|---|---|
[Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Diphosphates; Endothelial Cells; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Serine; Stilbenes; Tubulin Modulators; Xanthones | 2010 |
New vascular disrupting agents in upper gastrointestinal malignancies.
Topics: Angiogenesis Inhibitors; Animals; Bibenzyls; Diphosphates; Gastrointestinal Neoplasms; Humans; Neovascularization, Pathologic; Organophosphorus Compounds; Serine; Stilbenes; Upper Gastrointestinal Tract | 2014 |
1 other study(ies) available for combretastatin and serine
| Article | Year |
|---|---|
Cardiovascular toxicity profiles of vascular-disrupting agents.
Topics: Angiogenesis Inhibitors; Bibenzyls; Cardiovascular System; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Quinazolines; Serine; Xanthones | 2011 |